|
Synonyms: ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
ravulizumab is an approved drug (FDA (2018), EMA (2019))
Compound class:
Antibody
Comment: Ravulizumab (ALXN1210; Ultomiris) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab (Soliris), but was designed to have an inherently longer circulating half-life so as to extend dosing intervals to once/month [3].
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record. |
| References |
|
1. Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI et al.. (2019)
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood, 133 (6): 540-549. [PMID:30510079] |
|
2. Röth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H, Terriou L, Urbano-Ispizua Á, Wells RA, Jang JH et al.. (2018)
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv, 2 (17): 2176-2185. [PMID:30171081] |
|
3. Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y et al.. (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE, 13 (4): e0195909. [PMID:29649283] |
